BroadOak Capital Partners provided a senior term loan to refinance debt held by Interpace’s private equity stockholders, Ampersand Capital and 1315 Capital. Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic...
An investor group led by BroadOak Capital Partners acquired Particle Dynamics from Edgewater Capital Partners. Particle Dynamics is a global leader in particle processing, delivery technologies, and finished dose manufacturing for the pharmaceutical, over-the-counter, and nutraceutical markets. The full press release is below. Particle Dynamics Announces Sale...
Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the company to expand and industrialize its portfolio of single-use bioreactor systems and contract process development services. The full press release is below. PBS Biotech Raises $10M...
BroadOak portfolio company Vigene Biosciences was acquired by Charles River Laboratories. Vigene Biosciences is a leading CDMO providing viral vector manufacturing services for the cell and gene therapy market. The full press release is below. Charles River Laboratories Completes Acquisition of Vigene Biosciences WILMINGTON, Mass.–(BUSINESS WIRE)–Jun. 29, 2021–...
BroadOak Capital Partners invested growth capital in KromaTiD. KromaTiD sells structural genomic products and tech-enabled services to optimize gene editing for research and clinical purposes. The funding will help accelerate the commercialization of its recently launched direction genomic hybridization In-Site and SCREEN products for gene...
Genomenon announced that it has completed a $5.3M financing round in the company. The financing will enable the company to expand its commercial operations, which serve genetic testing labs, hospitals, pharmaceutical and biopharma companies. The full press release is below. Genomenon Completes $5.3M Financing Round AI-Driven Genomics Company...
BroadOak portfolio company Distributed Bio was acquired by Charles River Laboratories. Distributed Bio is a provider of innovative antibody discovery, engineering, informatics tools, and services for the life sciences research and drug discovery markets. The full press release is below. Charles River Laboratories Acquires Distributed Bio – Establishes...
BroadOak leads the formation and funding of a new ambulatory infusion platform, InFuse Holdings, to build a network of infusion centers throughout the Midwest. Initial funding used to acquire Cincinnati-based Horizon Infusions and provide growth capital for its expansion. The full press release is below. InFuse Holdings...
BroadOak portfolio company Akron Biotech was acquired by Arcline Investment Management. Akron is a provider of GMP-compliant cell-/gene-therapy and engineered tissue products and services. The full press release is below. Arcline Investment Management Acquires Majority Interest In Cell And Gene Therapy Materials Supplier Akron Biotechnology BOCA RATON, Fla.,...
Reaction Biology Corporation (“RBC”), a BroadOak portfolio company, completes a stock swap transaction whereby RBC acquires all the shares of ProQinase GmbH, an early stage drug discovery company based in Freiburg, Germany. RBC is an early stage drug discovery CRO specializing in biochemical and cell-based...
Stay connected
Partner with BroadOak